Special Discount for First-Timers from March 27-30

As first time participant at ECTS, if you register between 27 and 30 March 2017 you can benefit from the Early registration fee. Procedures:

  • Please register under the REGULAR FEE; at the end of the process please select the payment option “pay via bank transfer”
  • As soon as we verify that is the first time that you attend the ECTS congress, by 5 April the latest, we will contact you to send the payment details
  • Payment of the registration must be effective on 10 April the latest

Register here


Biomedica Immunoassays provides internationally recognized, high quality ELISAs for clinical research in the field of bone and mineral disorders as well as renal and cardiovascular diseases. Biomedica serves international academic scientific institutions, CROs, and laboratories in the pharmaceutical industry. All assays are fully validated according to ICH-Q2 guidelines and include serum-based calibrators and controls for biologically reliable data. New in the ELISA portfolio is Bioactive Sclerostin, soluble Semaphorin 4D, and Periostin. Since 2017, Biomedica exclusively distributes TAmiRNA’s osteomiR™ miRNA biomarker assay which serves as a novel fracture-risk assessment tool.
Visit us at our Biomedica booth # 9 (www.bmgrp.com).

Perkin Elmer

PerkinElmer is a global life sciences company uniquely positioned to bring instruments and software solutions to enable comprehensive imaging & detection solutions for your preclinical research. Our Quantum GX microCT imaging system combines high resolution microCT imaging with high-speed, low dose CT scanning across multiple species, ideal for bone and tissue research. When coupled with AccuCT™, our automated, advanced bone analysis software, researchers can perform ASBMR bone morphometry and BMD analysis with just a few clicks.  Stop by booth 16 and learn  how PerkinElmer preclinical solutions can work for you.


Immunodiagnostic Systems Limited is a leading in-vitro diagnostic solution provider to the clinical laboratory market. Our immunoassay portfolio is available for use on our fully-automated IDS-iSYS Multi-Discipline Automated System, or as stand-alone manual assay kits. This complete offering meets the needs of both clinical and research laboratories of all types and sizes with their diagnostic testing requirements. Immunodiagnostic Systems offers a unique and full panel of bone turnover markers, for the measurement and monitoring of bone resorption and formation markers which provide highly accurate and reliable results. For more product information visit us on stand 15 or go to www.idsplc.com


Offering the largest range of Preclinical Imaging systems, with an unmatched 9 in-vivo modalities, Bruker is committed to supporting the scientific community with high-end instruments dedicated to disease research, translational science and Molecular Imaging.

Benefitting from more than 5 decades of passionate innovation, Bruker customers enjoy a vast portfolio of possibility; from a single source they have endless opportunities for combining multiple modalities for seamless workflow and higher productivity.  Our non-invasive in-vivo imaging modalities are designed to deliver greater scientific insight based on animal-centric solutions.


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.